{"id":"loestrin","rwe":[],"tags":[],"safety":{"boxedWarnings":["WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC ) use. This risk increases with age , particularly in women over 35 years of age , and with the number of cigarettes smoked . For this reason, COCs should not be used by w omen who are over 35 years of age and smoke [ see Contraindications (4) ] . WARNING : CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See Full Prescribi"],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Gastrointestinal symptoms (abdominal cramps and bloating)","drugRate":"","severity":"common","organSystem":""},{"effect":"Breakthrough bleeding","drugRate":"","severity":"common","organSystem":""},{"effect":"Spotting","drugRate":"","severity":"common","organSystem":""},{"effect":"Change in menstrual flow","drugRate":"","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Breast tenderness","drugRate":"","severity":"common","organSystem":""},{"effect":"Edema","drugRate":"","severity":"common","organSystem":""},{"effect":"Change in weight","drugRate":"","severity":"common","organSystem":""},{"effect":"Migraine","drugRate":"","severity":"common","organSystem":""},{"effect":"Depression","drugRate":"","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"","severity":"common","organSystem":""},{"effect":"Nervousness","drugRate":"","severity":"common","organSystem":""},{"effect":"Vaginal candidiasis","drugRate":"","severity":"common","organSystem":""},{"effect":"Melasma","drugRate":"","severity":"common","organSystem":""},{"effect":"Acne","drugRate":"","severity":"common","organSystem":""},{"effect":"Rash (allergic)","drugRate":"","severity":"common","organSystem":""},{"effect":"Changes in appetite","drugRate":"","severity":"common","organSystem":""},{"effect":"Amenorrhea","drugRate":"","severity":"common","organSystem":""}],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Thrombophlebitis","drugRate":"","severity":"serious"},{"effect":"Pulmonary embolism","drugRate":"","severity":"serious"},{"effect":"Myocardial infarction","drugRate":"","severity":"serious"},{"effect":"Cerebral hemorrhage","drugRate":"","severity":"serious"},{"effect":"Cerebral thrombosis","drugRate":"","severity":"serious"},{"effect":"Arterial thromboembolism","drugRate":"","severity":"serious"},{"effect":"Mesenteric thrombosis","drugRate":"","severity":"serious"},{"effect":"Retinal thrombosis","drugRate":"","severity":"serious"},{"effect":"Hepatic adenomas or benign liver tumors","drugRate":"","severity":"serious"},{"effect":"Budd-Chiari syndrome","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":{"chemblId":"CHEMBL1201146","moleculeType":"Small molecule","molecularWeight":"340.46"},"aliases":["Ethinyl estradiol (EE) and norethindrone (NET)"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":{"setId":"f29ebcb5-7e65-4092-bfaa-f5ec026fc255","title":"LOESTRIN 21 DAY (NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL) TABLET LOESTRIN FE 28 DAY (NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE) KIT [TEVA WOMEN'S HEALTH LLC]"},"ecosystem":[],"mechanism":{},"_scrapedAt":"2026-03-28T06:12:38.921Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[],"indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07074327","phase":"PHASE1","title":"Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-07-11","conditions":"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","enrollment":74},{"nctId":"NCT07446400","phase":"PHASE1","title":"A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together","status":"NOT_YET_RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2026-03-20","conditions":"Healthy Volunteers","enrollment":48},{"nctId":"NCT01318005","phase":"NA","title":"Oral Contraceptive (OC) Estrogen Dose and Breast Proliferation","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2011-02-14","conditions":"Oral Contraceptive","enrollment":82},{"nctId":"NCT03106454","phase":"PHASE3","title":"Ovulation Incidence in Oral Contraceptive Users","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2014-08","conditions":"Contraception, Ovulation","enrollment":58},{"nctId":"NCT06310616","phase":"PHASE1","title":"A Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin) in Healthy Adult Female Participants","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2024-03-06","conditions":"HIV Infections","enrollment":26},{"nctId":"NCT01656434","phase":"PHASE3","title":"Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2012-11-02","conditions":"Contraception","enrollment":3173},{"nctId":"NCT05891262","phase":"PHASE1","title":"A Study to Evaluate the Drug-drug Interaction of BMS-986196 With Oral Contraceptives in Healthy Female Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2023-06-06","conditions":"Healthy Female Volunteers","enrollment":15},{"nctId":"NCT05579574","phase":"PHASE1","title":"A Study to Investigate the Interaction of BMS-986322 and a Combined Oral Hormonal Contraceptive (Ethinyl Estradiol [EE]/Norethindrone [NET]) in Healthy Female Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2022-10-21","conditions":"Healthy Participants","enrollment":42},{"nctId":"NCT02214550","phase":"PHASE4","title":"Chronic Pain Risk Associated With Menstrual Period Pain","status":"COMPLETED","sponsor":"Endeavor Health","startDate":"2014-07","conditions":"Cystitis, Interstitial, Dysmenorrhea, Migraine Disorders","enrollment":353},{"nctId":"NCT04016753","phase":"PHASE1","title":"A Study Measuring the Effectiveness of BMS-986256 Combined With Oral Contraceptive in Healthy Female Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-08-05","conditions":"Healthy Participants","enrollment":32},{"nctId":"NCT04934696","phase":"PHASE1","title":"A Study to Characterize the Drug Levels of an Oral Contraceptive With and Without BMS-986166 in Healthy Female Participants of Childbearing Potential","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2021-08-03","conditions":"Healthy Participants","enrollment":25},{"nctId":"NCT00125983","phase":"PHASE2","title":"Drug Interactions Between Lopinavir/Ritonavir and Oral or Patch Contraceptives in HIV Infected Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Pregnancy","enrollment":32},{"nctId":"NCT04709094","phase":"PHASE1","title":"A Drug Interaction Study of Danicopan","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2019-07-28","conditions":"Healthy","enrollment":52},{"nctId":"NCT02036879","phase":"EARLY_PHASE1","title":"Gender Disparity and Hormones in Cystic Fibrosis","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2014-02","conditions":"Cystic Fibrosis (CF)","enrollment":55},{"nctId":"NCT03262740","phase":"PHASE1","title":"The Effect of BMS-986195 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-09-11","conditions":"Rheumatoid Arthritis","enrollment":58},{"nctId":"NCT03262727","phase":"PHASE1","title":"The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-09-01","conditions":"Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis","enrollment":49},{"nctId":"NCT01953211","phase":"","title":"Oral Contraceptive Hormone-free Interval Pituitary/ Ovarian Activity","status":"COMPLETED","sponsor":"University of Southern California","startDate":"","conditions":"Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy","enrollment":64},{"nctId":"NCT00600106","phase":"NA","title":"Data Analyses for Ancillary WISE Femhrt Hormone Replacement Study","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"1999-12","conditions":"Myocardial Ischemia","enrollment":37},{"nctId":"NCT03451110","phase":"PHASE1","title":"Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2018-02-05","conditions":"Healthy Subjects","enrollment":50},{"nctId":"NCT00972439","phase":"NA","title":"Oral Contraceptive (OC) Progestin Dose and Breast Proliferation","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2007-08","conditions":"Oral Contraceptive","enrollment":33},{"nctId":"NCT02480881","phase":"PHASE1","title":"A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-07-07","conditions":"Infection, Human Immunodeficiency Virus","enrollment":26},{"nctId":"NCT01077505","phase":"PHASE1","title":"An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-03-15","conditions":"Diabetes Mellitus, Type 2","enrollment":16},{"nctId":"NCT02832180","phase":"PHASE1","title":"The Effect of BMS-986142 on the Pharmacokinetics of a Combined Oral Contraceptive (OC) Containing Ethinyl Estradiol (EE) and Norethindrone Acetate (NET) in Healthy Female Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-05","conditions":"Arthritis","enrollment":25},{"nctId":"NCT00704912","phase":"PHASE2","title":"Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2008-09","conditions":"Polycystic Ovary Syndrome","enrollment":217},{"nctId":"NCT02292732","phase":"PHASE1","title":"A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2016-02","conditions":"Cancer","enrollment":""},{"nctId":"NCT01209143","phase":"PHASE1","title":"A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2010-11","conditions":"Solid Cancers","enrollment":52},{"nctId":"NCT02245438","phase":"PHASE1","title":"Effect of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Norethindrone-Ethinyl Estradiol in Healthy Female Adult Volunteers","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2002-05","conditions":"Healthy","enrollment":52},{"nctId":"NCT02103569","phase":"PHASE1","title":"Drug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-04","conditions":"Hepatitis C","enrollment":20},{"nctId":"NCT02182791","phase":"PHASE1","title":"Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (VIRAMUNE) and Ethinyl Estradiol/Norethindrone in HIV-1 Infected Women","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-04","conditions":"HIV Infections","enrollment":14},{"nctId":"NCT00999479","phase":"NA","title":"Post Operative Continuous Active Combination Sex Steroids for the Prevention of Recurrent Endometrioma Formation","status":"WITHDRAWN","sponsor":"University of Oklahoma","startDate":"2009-10","conditions":"Endometrioma","enrollment":""},{"nctId":"NCT01297348","phase":"","title":"Study Of Lybrel In Relation To Venous Thromboembolism","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-07","conditions":"Venous Thrombosis, Pulmonary Embolism, Sinus Thrombosis, Intracranial","enrollment":598682},{"nctId":"NCT00000420","phase":"PHASE3","title":"Safety of Estrogens in Lupus: Birth Control Pills","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"1997-06","conditions":"Systemic Lupus Erythematosus","enrollment":350},{"nctId":"NCT00477633","phase":"PHASE3","title":"Study of Safety and Efficacy of an Oral Contraceptive","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2007-06","conditions":"Contraception","enrollment":1700},{"nctId":"NCT00391807","phase":"PHASE3","title":"Study of Safety and Efficacy of an Oral Contraceptive","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2006-11","conditions":"Contraception","enrollment":1683},{"nctId":"NCT01044498","phase":"PHASE3","title":"A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-12","conditions":"Rheumatoid Arthritis","enrollment":46},{"nctId":"NCT01200537","phase":"NA","title":"Optimizing Ovulation Induction in the Poor Responder","status":"WITHDRAWN","sponsor":"Duke University","startDate":"2010-10","conditions":"IVF Poor Responders","enrollment":""},{"nctId":"NCT01597986","phase":"PHASE1","title":"Drug Interaction Study of Isavuconazole and Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2012-04","conditions":"Pharmacokinetics of Isavuconazole, Pharmacokinetics of Ethinyl Estradiol and Norethindrone, Healthy Volunteers","enrollment":24},{"nctId":"NCT00504816","phase":"PHASE1","title":"A Study of the Effects of GSK189075 on PK Profiles of an Oral Contraceptive Pill When Given to Healthy Female Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04","conditions":"Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2","enrollment":22},{"nctId":"NCT00475189","phase":"NA","title":"Study of Loestrin 24(24 Days of \"Real\" Pills) Fe Versus Loestrin 1/20 (21 \"Real\" Pills)","status":"COMPLETED","sponsor":"Scott and White Hospital & Clinic","startDate":"2007-06","conditions":"Pelvic Pain, Headaches, Emotional","enrollment":51},{"nctId":"NCT01344369","phase":"PHASE1","title":"Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Non-Fasted Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2008-08","conditions":"Healthy","enrollment":36},{"nctId":"NCT01340625","phase":"PHASE1","title":"Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2006-12","conditions":"Bioequivalence","enrollment":36},{"nctId":"NCT00000897","phase":"NA","title":"A Study to Evaluate the Effects of Different Methods of Birth Control on the Drug Actions of Zidovudine (an Anti-HIV Drug) in HIV-Positive Women and to Compare Zidovudine Metabolism in Men and Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":42},{"nctId":"NCT00212277","phase":"PHASE3","title":"Efficacy and Safety,Long-term Study of Low-dose Oral Contraceptive Pill to Treat Dysmenorrhea.","status":"COMPLETED","sponsor":"Nobelpharma","startDate":"2005-02","conditions":"Dysmenorrhea","enrollment":""},{"nctId":"NCT01040845","phase":"PHASE1","title":"A Pharmacokinetic Study of Colchicine With an Oral Contraceptive","status":"COMPLETED","sponsor":"Mutual Pharmaceutical Company, Inc.","startDate":"2007-08","conditions":"Pharmacokinetics","enrollment":30},{"nctId":"NCT00821496","phase":"PHASE1","title":"Evaluate the Effect of VI-0521 on the Pharmacokinetics of Oral Contraceptive in Healthy Female Subjects","status":"COMPLETED","sponsor":"VIVUS LLC","startDate":"2009-01","conditions":"Healthy","enrollment":20},{"nctId":"NCT00656318","phase":"","title":"Impact of Oral Contraceptives on GABA and Neurosteroids","status":"TERMINATED","sponsor":"Yale University","startDate":"2008-08","conditions":"Healthy","enrollment":6},{"nctId":"NCT00732693","phase":"PHASE4","title":"Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2002-02","conditions":"Premature Ovarian Failure","enrollment":42},{"nctId":"NCT00004763","phase":"PHASE2","title":"Phase II Randomized Study of Leuprolide Vs Oral Contraceptive Therapy Vs Leuprolide and Oral Contraceptive Therapy for Ovarian Hyperandrogenism","status":"COMPLETED","sponsor":"National Center for Research Resources (NCRR)","startDate":"1993-01","conditions":"Hyperandrogenism","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[{"date":"20171010","type":"SUPPL","sponsor":"APIL","applicationNumber":"NDA022501"},{"date":"20211015","type":"SUPPL","sponsor":"APIL","applicationNumber":"NDA022501"},{"date":"20130508","type":"SUPPL","sponsor":"APIL","applicationNumber":"NDA022501"},{"date":"20220429","type":"SUPPL","sponsor":"APIL","applicationNumber":"NDA022501"},{"date":"20170809","type":"SUPPL","sponsor":"APIL","applicationNumber":"NDA022501"},{"date":"20130301","type":"SUPPL","sponsor":"APIL","applicationNumber":"NDA022501"},{"date":"20101021","type":"ORIG","sponsor":"APIL","applicationNumber":"NDA022501"},{"date":"20210818","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA076380"},{"date":"20041020","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA076380"},{"date":"20230925","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA076380"},{"date":"20230925","type":"SUPPL","sponsor":"BARR LABS","applicationNumber":"ANDA076380"},{"date":"20030530","type":"ORIG","sponsor":"BARR LABS","applicationNumber":"ANDA076380"},{"date":"20230925","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA076381"},{"date":"20210818","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA076381"},{"date":"20041020","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA076381"},{"date":"20030530","type":"ORIG","sponsor":"BARR","applicationNumber":"ANDA076381"},{"date":"20230925","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA076381"},{"date":"20230925","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA076081"},{"date":"20030918","type":"ORIG","sponsor":"BARR","applicationNumber":"ANDA076081"},{"date":"20230925","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA076081"},{"date":"20041020","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA076081"},{"date":"20210818","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA076081"},{"date":"20041020","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA076064"},{"date":"20230925","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA076064"},{"date":"20210818","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA076064"},{"date":"20230925","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA076064"},{"date":"20030918","type":"ORIG","sponsor":"BARR","applicationNumber":"ANDA076064"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":41,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Loestrin","genericName":"Loestrin","companyName":"ViiV Healthcare","companyId":"viiv-healthcare","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":true,"trials":true,"score":2}}